<DOC>
	<DOCNO>NCT00001038</DOCNO>
	<brief_summary>PRIMARY : To evaluate efficacy valacyclovir hydrochloride ( BW 256U87 ) prevention cytomegalovirus ( CMV ) end-organ disease HIV/CMV co-infected patient CD4+ lymphocytes &lt; 100 cells/mm3 . To assess impact BW 256U87 , high-dose oral acyclovir low-dose oral acyclovir survival . SECONDARY : To evaluate effect BW 256U87 quality life , safety drug administer concurrently standard antiretroviral agent essential therapy treatment prevention opportunistic disease , efficacy BW 256U87 suppress activation herpesviruses . To evaluate serologic virologic risk factor development CMV disease , include assessment HIV activation , risk develop drug-resistant CMV , HSV , VZV . Gastrointestinal absorption acyclovir high enough prevent CMV disease patient advance HIV disease , although evidence high dos drug may extend survival . Valacyclovir , prodrug rapidly convert acyclovir oral administration , high absorption rate may therefore provide inhibitory activity CMV .</brief_summary>
	<brief_title>A Study Valacyclovir Hydrochloride Prevention Life-Threatening Cytomegalovirus Disease HIV-Infected Patients</brief_title>
	<detailed_description>Gastrointestinal absorption acyclovir high enough prevent CMV disease patient advance HIV disease , although evidence high dos drug may extend survival . Valacyclovir , prodrug rapidly convert acyclovir oral administration , high absorption rate may therefore provide inhibitory activity CMV . Patients randomize receive BW 256U87 alone acyclovir alone control either high-dose low-dose . The acyclovir control provide suppressive therapy herpes simplex infection may affect survival .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Recommended : PCP prophylaxis . Allowed : Any antiretroviral therapy available prescription expand access Treatment IND program , include combination sequential use . Chemotherapy Kaposi 's sarcoma , lymphoma , malignancy IF patient hematologically stable least 30 day prior study entry . Discrete course oral parenteral acyclovir VZV HSV infection , exceed 21 day per episode ( may coenroll ACTG 169 ) . For recurrent episode , openlabel acyclovir total 60 day 12month period allow . Study drug interrupt . Supportive therapy available prescription , expand access , Treatment IND program , GCSF , GMCSF , erythropoietin . Other medication necessary patient 's welfare , discretion investigator . Patients must : HIV infection AIDSdefining condition . CD4+ count &lt; 100 cells/mm3 . IgG antibodies CMV . No active CMV disease history CMV endorgan disease . Consent parent guardian le 18 year age . Ability comply protocol . NOTE : Patients may coenrolled ACTG primary infection Phase II/III study , ACTG opportunistic infection protocol , treatment protocol similar study sponsor research network long study violate restriction place concomitant therapy toxicity management . Prior Medication : Allowed : PCP prophylaxis . Any antiretroviral therapy available prescription expand access Treatment IND program , include combination sequential use . Chemotherapy Kaposi 's sarcoma , lymphoma , malignancy . Acyclovir . Supportive therapy available prescription , expand access , Treatment IND program , GCSF , GMCSF , erythropoietin . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Nausea vomit precludes oral dosing . Ocular medium opacity preclude adequate visualization fundus . Pregnancy . Known hypersensitivity acyclovir . Known lactose intolerance . Concurrent Medication : Excluded : Systemic interferon immunomodulators ( include CMV hyperimmune serum/globulin chronic corticosteroid dose excess physiologic replacement ) . Probenecid . Investigational market agent potential activity CMV , herpes simplex , and/or Varicella zoster , EXCEPT specifically allow . Patients follow prior condition exclude : Preexisting necrotizing retinopathy may interfere subsequent diagnosis CMV retinitis . Prior Medication : Excluded : Prior ganciclovir , foscarnet , investigational antiCMV agent include use foscarnet acyclovirresistant herpes . Interferons , immunomodulators ( colony stimulate factor ) , CMV hyperimmune globulin within 30 day prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Cytomegalovirus Infections</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antiviral Agents</keyword>
</DOC>